Chemically modified compounds derived from cannabichromene (CBC), a cannabinoid found in cannabis, inhibited growth across multiple human cancer cell types in laboratory testing. Researchers synthesized a series of amine and amide analogues—modified versions of CBC—and screened them against the National Cancer Institute’s NCI-60 tumor cell panel.
Compounds 8 and 9 showed the strongest and broadest activity among the derivatives tested. Compound 9 was particularly active against PC-3 and DU-145 prostate cancer cells, inhibiting growth at low micromolar concentrations. It also induced apoptosis, the process of programmed cell death, in both prostate cancer cell lines.
The findings identify compound 9 as a promising starting point for further anticancer drug development. They highlight how CBC’s chemical structure can support the design of biologically active molecules, with further optimization and investigation needed to establish how these derivatives work.
“A novel series of cannabichromene-derived amine and amide analogues (4-13) was synthesized and evaluated for their anticancer activity against the NCI-60 human tumor cell line panel.
Among the synthesized derivatives, compounds 8 and 9 demonstrated the most potent and broad-spectrum anticancer activities, exhibiting significant percent growth inhibition across multiple cancer subtypes. Notably, compound 9 displayed good potency in prostate cancer cell lines PC-3 and DU-145, with GI50 values of 2.01 μM and 1.86 μM, respectively and pronounced cytotoxicity at higher concentrations. Its consistent performance across diverse cancer panels suggests a non-selective yet potent mechanism, likely targeting essential cellular pathways common to malignant cells. Compound 9 was found to induce apoptosis in PC-3 and DU-145 cells.
Collectively, these findings highlight 9 as a promising compound for further optimization and mechanistic exploration towards developing new anticancer leads derived from the cannabichromene scaffold.”
https://pubmed.ncbi.nlm.nih.gov/42924954
“In summary, the CBC amide analogues, particularly compounds 8 and 9, demonstrated significant anticancer potential across multiple NCI-60 cancer cell lines, exhibiting broad-spectrum cytotoxic activity.”